Adetayo Emmanuel Obasa1,2, Anoop T Ambikan3, Soham Gupta3, Ujjwal Neogi3, Graeme Brendon Jacobs4. 1. Department of Pathology, Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, 7505, South Africa. obasa@sun.ac.za. 2. Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska Institute, Stockholm, Sweden. obasa@sun.ac.za. 3. Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska Institute, Stockholm, Sweden. 4. Department of Pathology, Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, 7505, South Africa.
Abstract
BACKGROUND: HIV-1C has been shown to have a greater risk of virological failure and reduced susceptibility towards boosted protease inhibitors (bPIs), a component of second-line combination antiretroviral therapy (cART) in South Africa. This study entailed an evaluation of HIV-1 drug resistance-associated mutations (RAMs) among minor viral populations through high-throughput sequencing genotypic resistance testing (HTS-GRT) in patients on the South African national second-line cART regimen receiving bPIs. METHODS: During 2017 and 2018, 67 patient samples were sequenced using high-throughput sequencing (HTS), of which 56 samples were included in the final analysis because the patient's treatment regimen was available at the time of sampling. All patients were receiving bPIs as part of their cART. Viral RNA was extracted, and complete pol genes were amplified and sequenced using Illumina HiSeq2500, followed by bioinformatics analysis to quantify the RAMs according to the Stanford HIV Drug Resistance Database. RESULTS: Statistically significantly higher PI RAMs were observed in minor viral quasispecies (25%; 14/56) compared to non-nucleoside reverse transcriptase inhibitors (9%; 5/56; p = 0.042) and integrase inhibitor RAM (4%; 2/56; p = 0.002). The majority of the drug resistance mutations in the minor viral quasispecies were observed in the V82A mutation (n = 13) in protease and K65R (n = 5), K103N (n = 7) and M184V (n = 5) in reverse transcriptase. CONCLUSIONS: HTS-GRT improved the identification of PI and reverse transcriptase inhibitor (RTI) RAMs in second-line cART patients from South Africa compared to the conventional GRT with ≥20% used in Sanger-based sequencing. Several RTI RAMs, such as K65R, M184V or K103N and PI RAM V82A, were identified in < 20% of the population. Deep sequencing could be of greater value in detecting acquired resistance mutations early.
BACKGROUND: HIV-1C has been shown to have a greater risk of virological failure and reduced susceptibility towards boosted protease inhibitors (bPIs), a component of second-line combination antiretroviral therapy (cART) in South Africa. This study entailed an evaluation of HIV-1 drug resistance-associated mutations (RAMs) among minor viral populations through high-throughput sequencing genotypic resistance testing (HTS-GRT) in patients on the South African national second-line cART regimen receiving bPIs. METHODS: During 2017 and 2018, 67 patient samples were sequenced using high-throughput sequencing (HTS), of which 56 samples were included in the final analysis because the patient's treatment regimen was available at the time of sampling. All patients were receiving bPIs as part of their cART. Viral RNA was extracted, and complete pol genes were amplified and sequenced using Illumina HiSeq2500, followed by bioinformatics analysis to quantify the RAMs according to the Stanford HIV Drug Resistance Database. RESULTS: Statistically significantly higher PI RAMs were observed in minor viral quasispecies (25%; 14/56) compared to non-nucleoside reverse transcriptase inhibitors (9%; 5/56; p = 0.042) and integrase inhibitor RAM (4%; 2/56; p = 0.002). The majority of the drug resistance mutations in the minor viral quasispecies were observed in the V82A mutation (n = 13) in protease and K65R (n = 5), K103N (n = 7) and M184V (n = 5) in reverse transcriptase. CONCLUSIONS: HTS-GRT improved the identification of PI and reverse transcriptase inhibitor (RTI) RAMs in second-line cART patients from South Africa compared to the conventional GRT with ≥20% used in Sanger-based sequencing. Several RTI RAMs, such as K65R, M184V or K103N and PIRAMV82A, were identified in < 20% of the population. Deep sequencing could be of greater value in detecting acquired resistance mutations early.
Authors: Birgitte B Simen; Michael S Braverman; Isabella Abbate; Jeroen Aerssens; Yannick Bidet; Olivier Bouchez; Christian Gabriel; Jacques Izopet; Harald H Kessler; Evelyn Stelzl; Francesca Di Giallonardo; Ralph Schlapbach; Aleksander Radonic; Roger Paredes; Patricia Recordon-Pinson; James Sakwa; Elizabeth P St John; Gudrun G Schmitz-Agheguian; Karin J Metzner; Martin P Däumer Journal: J Virol Methods Date: 2014-04-13 Impact factor: 2.014
Authors: Seth C Inzaule; Raph L Hamers; Marc Noguera-Julian; Maria Casadellà; Mariona Parera; Tobias F Rinke de Wit; Roger Paredes Journal: J Antimicrob Chemother Date: 2018-05-01 Impact factor: 5.790
Authors: Jonathan Z Li; Roger Paredes; Heather J Ribaudo; Evguenia S Svarovskaia; Karin J Metzner; Michael J Kozal; Kathy Huppler Hullsiek; Melanie Balduin; Martin R Jakobsen; Anna Maria Geretti; Rodolphe Thiebaut; Lars Ostergaard; Bernard Masquelier; Jeffrey A Johnson; Michael D Miller; Daniel R Kuritzkes Journal: JAMA Date: 2011-04-06 Impact factor: 56.272
Authors: John Archer; Michael S Braverman; Bruce E Taillon; Brian Desany; Ian James; P Richard Harrigan; Marilyn Lewis; David L Robertson Journal: AIDS Date: 2009-06-19 Impact factor: 4.177
Authors: Hezhao Ji; Eric Enns; Chanson J Brumme; Neil Parkin; Mark Howison; Emma R Lee; Rupert Capina; Eric Marinier; Santiago Avila-Rios; Paul Sandstrom; Gary Van Domselaar; Richard Harrigan; Roger Paredes; Rami Kantor; Marc Noguera-Julian Journal: J Int AIDS Soc Date: 2018-10 Impact factor: 5.396
Authors: Susana Posada-Céspedes; Gert Van Zyl; Hesam Montazeri; Jack Kuipers; Soo-Yon Rhee; Roger Kouyos; Huldrych F Günthard; Niko Beerenwinkel Journal: PLoS Comput Biol Date: 2021-09-07 Impact factor: 4.475